TWO COMPONENT SEALING SYSTEMS INCLUDING SYNTHETIC MATRICES AND BIOSYNTHETIC ADHESIVES FOR SEALING RESECTED SURFACES OF ORGANS TO CONTROL BLEEDING, FLUID LEAKS AND AIR LEAKS

Abstract

A method of sealing a resected surface of an organ includes applying a synthetic matrix to a resected surface of an organ, and applying an adhesive on the synthetic matrix so that the adhesive penetrates through interstices of the synthetic matrix for contacting an interface between the synthetic matrix and the resected surface of the organ. The method includes curing the adhesive for bonding the synthetic matrix to the resected surface of the organ. The synthetic matrix is a non-woven mesh made of polyglactin 910 or any other synthetic or non-synthetic fabric having a similar porosity or density. The adhesive is a biosynthetic or a synthetic adhesive. After penetrating through the pores of the synthetic matrix and curing, the cured biosynthetic or synthetic adhesive mechanically interlocks with the synthetic matrix for adhering the synthetic matrix to the tissue for creating a sealing barrier.

Claims

1. A method of sealing a resected surface of an organ comprising: applying a synthetic matrix to a resected surface of an organ; applying an adhesive on said synthetic matrix so that said adhesive penetrates through interstices of said synthetic matrix for contacting an interface between said synthetic matrix and the resected surface of said organ; curing said adhesive for bonding said synthetic matrix to the resected surface of said organ.

2. The method as claimed in claim 1, wherein said synthetic matrix is a biodegradable, porous, flexible substrate.

3. The method as claimed in claim 1, wherein said synthetic matrix comprises a non-woven mesh made of polyglactin 910.

4. The method as claimed in claim 1, wherein said synthetic matrix and said adhesive are at least partially transparent.

5. The method as claimed in claim 1, wherein said synthetic matrix comprises fibers and has a density range of 102.7-190.7 mg/cm.sup.3.

6. The method as claimed in claim 1, wherein said synthetic matrix comprises fibers and has a density range of 128.7-190.7 mg/cm.sup.3.

7. The method as claimed in claim 1, wherein said adhesive comprises a biosynthetic adhesive or a synthetic adhesive.

8. The method as claimed in claim 1, wherein said adhesive comprises a biocompatible, reactive electrophile and a nucleophile.

9. The method as claimed in claim 8, wherein said electrophile comprises a polyethylene glycol succinimidyl glutarate ester (PEG-SG).

10. The method as claimed in claim 9, wherein said nucleophophile is selected from the group consisting of any source of amine (NH.sub.2) groups, any appropriate protein or protein mixture, albumin, polyethylene glycol amines (PEG-NH.sub.2), and combinations of albumin and PEG-NH.sub.2.

11. The method as claimed in claim 7, wherein said biosynthetic adhesive comprises a partially hydrolyzed protein and PEG-SG.

12. The method as claimed in claim 11, wherein said partially hydrolyzed protein comprises albumin.

13. The method as claimed in claim 12, wherein said biosynthetic adhesive comprises a mixture of a 10% albumin solution and 75 mg/ml of PEG-SG solution.

14. The method as claimed in claim 1, wherein said adhesive is in a liquid or powder form and is cross-linked with fibers of said synthetic matrix.

15. A method of sealing a resected surface of an organ comprising: applying a porous, bioabsorbable synthetic matrix made of polyglactin 910 to a resected surface of an organ; applying an adhesive on said synthetic matrix so that said adhesive penetrates through pores of said synthetic matrix for contacting an interface between said synthetic matrix and the resected surface of said organ; curing said adhesive for bonding said synthetic matrix to the resected surface of said organ.

16. The method as claimed in claim 15, wherein said adhesive is a biosynthetic adhesive or a synthetic adhesive.

17. The method as claimed in claim 15, wherein said synthetic matrix comprises fibers and has a density range of 102.7-190.7 mg/cm.sup.3, and wherein said cured adhesive is cross-linked with said fibers of said synthetic matrix.

18. The method as claimed in claim 15, wherein said synthetic matrix comprises fibers and has a density range of 128.7-190.7 mg/cm.sup.3, and wherein said cured adhesive is cross-linked with said fibers of said synthetic matrix.

19. The method as claimed in claim 15, further comprising: prior to the applying a porous, bioabsorbable synthetic matrix step, pre-applying said adhesive on the resected surface of said organ.

20. A kit for sealing a resected surface of an organ comprising: a synthetic matrix comprising a non-woven mesh made of polyglactin 910; an adhesive comprising a biocompatible, reactive electrophile and a nucleophile.

21. The kit as claimed in claim 20, wherein said adhesive is a biosynthetic adhesive comprising a partially hydrolyzed protein and PEG-SG.

22. The kit as claimed in claim 21, further comprising: a dual syringe for dispensing said biosynthetic adhesive including a first syringe barrel and a second syringe barrel; said first syringe barrel containing a 20% albumin solution; and said second syringe barrel containing a 150 mg/ml of PEG-SG solution.

23. The kit as claimed in claim 20, wherein said synthetic matrix is porous and has a density range of 102.7-190.7 mg/cm.sup.3.

24. The method as claimed in claim 20, wherein said synthetic matrix is porous and has a density range of 128.7-190.7 mg/cm.sup.3.

25. The kit as claimed in claim 20, wherein said adhesive is in liquid or powder form.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0053] FIG. 1 shows the chemical formula for polyethylene glycol succinimidyl glutarate (PEG-SG) that is a part of a biosynthetic adhesive, in accordance with one embodiment of the present patent application.

[0054] FIG. 2 shows a schematic example of a protein (albumin) that is part of a biosynthetic adhesive, in accordance with one embodiment of the present patent application.

[0055] FIG. 3 is a top view of a synthetic matrix, in accordance with one embodiment of the present patent application.

[0056] FIG. 4 shows a schematic example of combining a biosynthetic adhesive and a synthetic matrix, in accordance with one embodiment of the present patent application.

[0057] FIG. 5 shows a schematic examples of a biosynthetic adhesive cross-linked with a synthetic matrix for sealing a resected surface of tissue, which is represented by the letter T, in accordance with one embodiment of the present patent application.

[0058] FIG. 6 is a synthetic matrix of a two component sealant used for sealing a resected surface of tissue, in accordance with one embodiment of the present patent application.

[0059] FIG. 7 shows the synthetic matrix of FIG. 6 secured to a 45 degree inclined plane following application of a 10% albumin, 75 mg/ml 4 Arm PEG-SG-10K, 50 mM carbonate (pH=8.0) biological adhesive, in accordance with one embodiment of the present patent application.

[0060] FIG. 8 is a graph that plots the retention and penetration of a biosynthetic adhesive into synthetic matrices having different density levels, in accordance with one embodiment of the present patent application.

[0061] FIG. 9 is a graph that plots the penetration of a biosynthetic adhesive through synthetic matrices having different density levels, in accordance with one embodiment of the present patent application.

[0062] FIG. 10 has two arrows that show the depth of penetration of a biosynthetic adhesive through a first synthetic matrix (Matrix 1) having a density of 93.0 mg/cm.sup.3, in accordance with one embodiment of the present patent application.

[0063] FIG. 11 has two arrows that show the depth of penetration of a biosynthetic adhesive through a second synthetic matrix (Matrix 2) having a density of 120.5 mg/cm.sup.3, in accordance with one embodiment of the present patent application.

[0064] FIG. 12 has two arrows that show the depth of penetration of a biosynthetic adhesive through a third synthetic matrix (Matrix 3) having a density of 131.2 mg/cm.sup.3, in accordance with one embodiment of the present patent application.

[0065] FIG. 13 has two arrows that show the depth of penetration of a biosynthetic adhesive through a fourth synthetic matrix (Matrix 4) having a density of 178.2 mg/cm.sup.3, in accordance with one embodiment of the present patent application.

[0066] FIG. 14 has two arrows that show the depth of penetration of a biosynthetic adhesive through a fifth synthetic matrix (Matrix 5) having a density of 247.0 mg/cm.sup.3, in accordance with one embodiment of the present patent application.

[0067] FIG. 15 is a graph that plots the burst pressure levels for synthetic matrices having different density levels, in accordance with one embodiment of the present patent application.

[0068] FIG. 16 is a graph that plots the burst pressure levels for synthetic matrices having different density levels for soft tissue resection and high pressure bleeding, in accordance with one embodiment of the present patent application.

[0069] FIG. 17 is a graph that plots the burst pressure levels for synthetic matrices having different density levels, in accordance with one embodiment of the present patent application.

[0070] FIG. 18A shows a method of resecting a liver, in accordance with one embodiment of the present patent application.

[0071] FIG. 18B shows a method of placing a synthetic matrix over a resected surface of the liver shown in FIG. 18A, in accordance with one embodiment of the present patent application.

[0072] FIG. 180 shows the synthetic matrix of FIG. 18B after a biosynthetic adhesive has been applied to the synthetic matrix for sealing the resected surface of the liver shown in FIG. 18A, in accordance with one embodiment of the present patent application.

[0073] FIG. 19A shows a first stage of a surgical method including resecting a liver lobe, in accordance with one embodiment of the present patent application.

[0074] FIG. 19B shows a second stage of a surgical method including spraying a biosynthetic adhesive onto the resected surface of the liver lobe, in accordance with one embodiment of the present patent application

[0075] FIG. 190 shows a third stage of a surgical method including placing a synthetic matrix over the sprayed, resected surface of the liver lobe, in accordance with one embodiment of the present patent application

[0076] FIG. 19D shows the synthetic matrix of FIG. 190 after being sprayed with the biosynthetic adhesive sealant.

[0077] FIG. 19E shows a curing stage for the biosynthetic adhesive.

[0078] FIG. 19F shows another stage of a surgical method including removing a clamp and re-establishing blood flow to the resected liver lobe, in accordance with one embodiment of the present patent application

[0079] FIG. 19G shows the resected surface of the liver lobe after the synthetic matrix has been peeled away to demonstrate that bleeding will recommence if the synthetic matrix is removed from the resected surface of the liver lobe.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0080] In one embodiment, a two component sealant is preferably applied to the resected surfaces of soft organs to prevent intra and post-operative bleeding, fluid leaks (e.g., bile), and/or air leaks (e.g., lungs) from the resected surfaces.

[0081] Referring to FIGS. 1 and 2, in one embodiment, a two component sealant for resected surfaces of soft organs preferably includes an adhesive 100, such as a biosynthetic adhesive, that may be applied in a liquid or powder form onto a synthetic matrix. In one embodiment, a biosynthetic adhesive may be a solution that includes a mixture of polyethylene glycol succinimidyl glutarate, also known as PEG-SG, and a protein (e.g., albumin).

[0082] Polyethylene glycol succinimidyl glutarate (PEG-SG) has a well-established safety profile in medical devices and has been used in sealant products such as Duraseal and Coseal. The succinimidyl glutarate reacts with amine groups on proteins, e.g., collagen, under mildly alkaline conditions forming an amide bond. The cleavable ester linker designed into the PEG enables the polymer to be degradable in vivo. This form of PEG also provides the ability to cross-link across multiple collagen fibers due to its long spacer region allowing intermolecular cross-linking.

[0083] FIG. 1 shows the chemical structure for the polyethylene glycol succinimidyl glutarate (i.e., PEG-SG).

[0084] FIG. 2 shows a simplified schematic for the protein (i.e., albumin).

[0085] Referring to FIG. 3, in one embodiment, the two component sealant preferably includes a synthetic matrix 102 that is adapted to be placed onto the resected surface of a soft organ. In one embodiment, the synthetic matrix 102 may be a mesh matrix or a non-woven matrix that is placed on the resected surface together with the biosynthetic adhesive 100 (FIGS. 1 and 2). In one embodiment, the non-woven matrix is flexible and/or conformable and is adapted for being placed onto a resected tissue surface, with the biosynthetic adhesive 100 being applied to the synthetic matrix 102.

[0086] In one embodiment, the synthetic matrix 102 preferably includes fibers 104 and interstices 106 that are disposed between the fibers 104.

[0087] In one embodiment, the biosynthetic adhesive is a cross-linkable liquid adhesive that is applied to the non-woven matrix 102. The biosynthetic adhesive is adapted to permeate through the interstices 106 of the synthetic matrix so that the synthetic matrix 102 will retain the biosynthetic adhesive, whereupon the adhesive will cure and mechanically interlock and/or chemically cross-link with the fibers 104 of the synthetic matrix 102.

[0088] In one embodiment, the density of the synthetic matrix 102 may be tailored (i.e., optimized) to maximize the ability of the adhesive to attach to tissue and the cohesiveness of the sealant to form a non-permeable mechanical barrier that covers the resected surface of the organ. In one embodiment, the adhesiveness and cohesiveness may be assessed together by evaluating the system's ability to withstand normal pressure applied to a major surface of the synthetic matrix 102.

[0089] Referring to FIGS. 4 and 5, in one embodiment, after the synthetic matrix 102 is applied over a resected surface of tissue T, the biosynthetic adhesive 100 may be applied to the surface of the synthetic matrix 102 that faces away from the resected surface of the tissue T. In one embodiment, the density of the synthetic matrix 102 is selected to be sufficiently low enough to allow the biosynthetic adhesive 100 to penetrate completely through the thickness of the synthetic matrix 102 and reach the resected surface of the tissue, whereupon the biosynthetic adhesive 100 can cure and cross-link with the surface molecules to achieve adhesion to the underlying tissue. In one embodiment, the biosynthetic adhesive 100 is preferably formulated so that it fully penetrates through the interstices of the synthetic matrix 102 to create a cohesive cross-linked hydrogel that incorporates the fibers of the synthetic matrix, which serves as a reinforcement scaffold that seals the resected surface of the tissue T.

[0090] In one embodiment, the cohesiveness resulting from the cross-linked hydrogel reinforcement may be increased by controlling the density of the synthetic matrix 102.

[0091] In one embodiment, the design parameters for the synthetic matrix 102 are selected to optimize the ability of the synthetic matrix to retain the biosynthetic adhesive 100 for a sufficient period of time to enable the adhesive to cure and mechanically interlock and/or to chemically cross-link with the fibers 104 of the synthetic matrix 102, which, in turn, optimizes the cohesive properties of the two component sealant. The ability of the synthetic matrix to retain the biosynthetic adhesive is preferably increased by increasing the matrix density up to a predetermined density level (i.e., a critical point, an optimized density level). Beyond the predetermined density level, the synthetic matrix will be too dense to allow for sufficient penetration of the biosynthetic adhesive through the thickness of the synthetic matrix and retention of the biosynthetic adhesive by the synthetic matrix.

[0092] In one embodiment, the specification and design parameters for the biosynthetic adhesive 100 and the synthetic matrix 102 are established by identifying an optimal matrix density range that maximizes penetration of the biosynthetic adhesive (e.g., a liquid) through the thickness of the synthetic matrix, retention of the biosynthetic adhesive by the synthetic matrix, and the system's ability to withstand pressure resulting from bleeding, fluid leaks, and air leaks, thereby maximizing the functionality of the two component sealant to stop bleeding and seal fluid and air leaks.

[0093] In one embodiment, the synthetic matrix (e.g., VICRYL® PG910 mesh) may be functionalized with amine groups to enable formation of covalent bonds between the synthetic matrix and the PEG molecules (i.e., PEG-SG), which will eventually covalently bind the synthetic matrix molecules to the tissue. A protein solution or a partially digested protein may be applied to the synthetic matrix and the resected area as disclosed herein as a PEG-SG substrate to form a sealant.

[0094] FIGS. 4 and 5 show the reaction of the PEG-SG4 (4-arm version) with albumin. The amine (NH.sub.2) groups of the protein (e.g., primary amine moieties), which are depicted in FIGS. 4 and 5, react with the succinimidyl glutarate of the PEG forming a covalent (amide) bond. The PEG-SG4 is also capable of reacting with proteins on the tissue surface (e.g., collagen), providing adhesion of the cross-linked polymer to the tissue surface.

[0095] In one embodiment, an experiment was conducted to determine optimal density levels for synthetic matrices. In one embodiment, five matrices were evaluated, each matrix having a comparable volume but a different density. In one embodiment, a first synthetic matrix specimen (i.e., Matrix 1) had a density of about 93.0 mg/cm.sup.3; a second synthetic matrix specimen (i.e., Matrix 2) had a density of about 120.5 mg/cm.sup.3; a third synthetic matrix specimen (i.e., Matrix 3) had a density of about 131.2 mg/cm.sup.3; a fourth synthetic matrix specimen (i.e., Matrix 4) had a density of about 178.2 mg/cm.sup.3; and a fifth synthetic matrix specimen (i.e., Matrix 5) had a density of about 247.0 mg/cm.sup.3. A chart depicting the different densities for the five different specimens is set forth below.

TABLE-US-00001 Average Density Standard Density Deviation (mg/cm.sup.3) (mg/cm.sup.3) Matrix 1 93.0 21.9 Matrix 2 120.5 20.0 Matrix 3 131.2 31.5 Matrix 4 178.2 39.9 Matrix 5 247.0 32.7

[0096] Referring to FIGS. 6 and 7, in one embodiment, in order to assess the ability of the different matrices 102 to absorb and retain a biosynthetic adhesive, each matrix was sized to be a 6×6 cm square matrix. In one embodiment, each matrix held on a test board 108 at an approximately 45 degree angle. In one embodiment, a biosynthetic adhesive (i.e., 10% albumin, 75 mg/mL 4 Arm PEG-SG-10k, 50 mM carbonate at pH=8.0) was sprayed onto each 6×6 cm square matrix using a spray device such as an Evicel® Airless Spray Accessory. After being applied to the synthetic matrix 102, the biosynthetic adhesive was allowed to cure for two minutes. Each matrix was assessed to determine the retention of the biosynthetic adhesive by the synthetic matrix and the penetration of the biosynthetic adhesive through the thickness of the synthetic matrix.

[0097] In one embodiment, the retention of the biosynthetic adhesive by each of the five synthetic matrix samples (i.e., Matrix 1, Matrix 2, Matrix 3, Matrix 4, and Matrix 5) was measured gravimetrically. In other words, synthetic matrix samples having different densities were studied to evaluate retention of the biosynthetic adhesive. A one-way ANOVA test was used to demonstrate that there were significant differences in permeation and retention at different densities (p<0.05). The synthetic matrix specimen (i.e., Matrix 4) having a density of 178.2 mg/cm.sup.3 was observed to result in the greatest biosynthetic adhesive retention while the least biosynthetic adhesive retention was observed when testing the synthetic matrix specimen (i.e., Matrix 1) having a density of 93.0 mg/cm.sup.3, and the synthetic matrix specimen (i.e., Matrix 5) having a density of 247 mg/cm.sup.3. The fourth matrix specimen (i.e., Matrix 4) having a density of 178.2 mg/cm.sup.3 represented a 75%, 25%, 23%, and 80% increase in biosynthetic adhesive retention relative to the other specimens at 93.0 mg/cm.sup.3 120.5 mg/cm.sup.3, 131.2 mg/cm.sup.3, and 247 mg/cm.sup.3 conditions, respectively.

[0098] In one embodiment, the ability of the biosynthetic adhesive to penetrate or traverse through the synthetic matrix specimens having different densities was assessed via confocal microscopy. In one embodiment, a cross-section of each synthetic matrix was imaged and measured via image processing methods.

[0099] The biosynthetic adhesive retention and biosynthetic adhesive penetration data are shown together in FIG. 8. At low matrix densities, the biosynthetic adhesive can completely penetrate through the synthetic matrix. As the density of the matrix increases, there is an increase in the ability of the matrix to absorb the biosynthetic adhesive. At a critical point, however, the matrix density becomes too great to allow the biosynthetic adhesive to completely penetrate through the depth of matrix, and the biosynthetic adhesive can no longer pass completely through the matrix as was the case at lower matrix densities. The inability of the sealant to penetrate through the matrix then decreases the ability of the matrix to retain the sealant, which results in the sealant simply running off the exposed surface of the matrix. Without complete sealant penetration of the matrix, the sealant is unable to bind to the underlying tissue in vivo.

[0100] As documented in the graph shown in FIG. 8, a Kruskal-Wallis test demonstrated that there was complete penetration of the biosynthetic adhesive through the fourth synthetic matrix specimen (i.e., Matrix 4) having a matrix density of 178.2 mg/cm.sup.3 after which there was a significant 73% drop in penetration through denser synthetic matrices. In the graph shown in FIG. 8, the error bars represent one (1) standard deviation.

[0101] FIG. 9 is a graph that shows the penetration of the biosynthetic adhesive through the thickness of the matrix specimens at different matrix densities. Due to the nature of the PG910 matrix, as the density of the matrix increases, there is a corresponding increase in the thickness of the matrix itself. Up to a matrix density of 178.2 mg/cm3, the sealant completely penetrates through the matrix and the thickness of the biosynthetic adhesive increases, as well. Above the matrix density of 178.2 mg/cm3, although the matrix thickness continues to increase, the thickness of the biosynthetic adhesive will dramatically decrease due to poor penetration of the biosynthetic adhesive through the matrix. For example, at a matrix density of 247 mg/cm.sup.3, the distance of the biosynthetic adhesive penetration through the matrix is 52% lower than the penetration through a matrix specimen having density of 178.2 mg/cm.sup.3. In the graph shown in FIG. 9, the error bars represent one (1) standard deviation.

[0102] FIGS. 10-14 shows representative confocal microscopy images of penetration of the biosynthetic adhesive through the thicknesses of five synthetic matrix specimens having different densities. In FIGS. 10-14, the distance between the two red arrows indicates the sealant penetration through the respective matrix.

[0103] FIG. 10 shows a first matrix specimen (Matrix 1) having a density of 93.0 mg/cm.sup.3. FIG. 11 shows a second matrix specimen (Matrix 2) having a density of 120.5 mg/cm.sup.3. FIG. 12 shows a third matrix specimen (Matrix 3) having a density of 131.2 mg/cm.sup.3. FIG. 13 shows a fourth matrix specimen (Matrix 4) having a density of 178.2 mg/cm.sup.3, FIG. 14 shows a fifth matrix specimen (Matrix 5) having a density of 247.0 mg/cm.sup.3.

[0104] The synthetic matrix specimens having densities of 93.0-178.2 mg/cm.sup.3 (i.e., Matrix Specimens 1-4) were completely penetrated by the biosynthetic adhesive. The penetration of the biosynthetic adhesive through the synthetic matrix specimen having a density of 247.0 mg/cm.sup.3 (Matrix Specimen 5 shown in FIG. 14) was 52% less than for the synthetic matrix specimen having densities of 178.2 mg/cm.sup.3 (Matrix Specimen 4 shown in FIG. 13).

[0105] In one embodiment, the functional consequences of the observed differences in retention and penetration of the biosynthetic adhesive were assessed via a benchtop hydraulic burst pressure test. In one embodiment, a synthetic matrix specimen with previously cured biosynthetic adhesive was mounted on the test fixture. Saline was pumped underneath the matrix specimen at a rate of 2 mL/min until failure. The maximum pressure at failure was recorded. Synthetic matrix specimens having the five different density levels disclosed herein were evaluated. Referring to FIG. 15, the synthetic matrix specimen having a density of 178 mg/cm.sup.3 (i.e., Matrix 4 shown in FIG. 13) attained a burst pressure of 317 mmHg, which was 73 times greater than the synthetic matrix specimen having a density of 93.0 cm/mg.sup.3 (i.e., Matrix 1 in FIG. 10), six (6) times greater than the synthetic matrix specimen having a density of 120.5 cm/mg.sup.3 (i.e., Matrix 2 in FIG. 11), 1.78 times greater than the synthetic matrix specimen having a density of 131.2 cm/mg.sup.3 (i.e., Matrix 3 in FIG. 12), and five (5) times greater than the synthetic matrix specimen having a density of 247 mg/cm.sup.3 (i.e., Matrix 5 in FIG. 14). In the graph shown in FIG. 15, the error bars represent one (1) standard deviation. As a result of testing using the Welch ANOVA test, it was determined that the synthetic matrix specimen having a density of 178 mg/cm.sup.3 (i.e., Matrix 4 in FIG. 13) was significantly greater at sealing the resected surfaces of organs than the other synthetic matrix specimens having different densities.

[0106] In soft tissue resection, pressures of 9 mm Hg can be expected, however, in one embodiment, a safety factor of 3 is preferably applied to ensure desired performance. In high pressure bleeding, the upper limit of clinical pressures can reach 160 mmHg.

[0107] Referring to FIG. 16, in order to determine the minimum required matrix density for adequate sealing, a quadratic regression model was generated in Microsoft Excel for the burst pressure data vs. matrix density (R.sup.2=83.65%). A response optimizer algorithm in Minitab 18 was employed to determine the minimum matrix density that would result in a burst pressure of 27 mmHg and of 160 mmHg. The minimum matrix density was calculated to be 102.7 mg/cm.sup.3 and 128.7 mg/cm.sup.3, respectively. In the graph shown in FIG. 16, the error bars represent one (1) standard deviation.

[0108] Referring to FIG. 17, the maximum matrix density for adequate sealing is restricted to a density that allows for complete penetration of the biosynthetic adhesive through the thickness of the synthetic matrix. A quadratic regression model was calculated in Microsoft Excel for the sealant thickness data (R.sup.2=97.35%). The maximum matrix density was defined as the matrix density that resulted in sealant penetration greater than the average thickness of the matrices tested (i.e., 430 μm). A response optimizer algorithm in Minitab 18 was employed to determine that the maximum matrix density that would result in a biosynthetic adhesive penetration of 430 μm corresponded to a matrix density value of 190.7 mg/cm.sup.3. In the graph shown in FIG. 17, the error bars represent one (1) standard deviation.

[0109] Therefore, in one embodiment, the optimal matrix density employed for sealing a soft tissue resection is about 102-191 mg/cm.sup.3 and more preferably 102.7-190.7 mg/cm.sup.3 and the optimal matrix density employed for sealing high pressure bleeding is about 128-191 mg/cm.sup.3, and more preferably 128.7-190.7 mg/cm.sup.3.

[0110] To demonstrate that a synthetic matrix at the selected density works properly to seal a resected surface, a synthetic matrix specimen having a density of 107.9 mg/cm.sup.3 was used on a liver partial lobe resection and showed that it is effective in reaching hemostasis.

[0111] Referring to FIG. 18A, in one embodiment, a liver undergoes a partial lobe resection. Referring to FIGS. 18B and 18C, a synthetic matrix 102 having a density of 107.9 mg/cm.sup.3 and a biosynthetic adhesive are applied on the partial lobe resection of the liver using the systems, devices and methods disclosed herein. The combination of the synthetic matrix and the biosynthetic adhesive sealed the resected surface, prevented bleeding and fluid leaks, and reached hemostasis.

[0112] In one embodiment, a sealant including a synthetic mesh and a biosynthetic adhesive are applied together onto a resected surface of a soft organ. The synthetic mesh and the biosynthetic adhesive may be applied in different forms and methods as described below in order to control bleeding, fluid leaks, and air leaks.

[0113] In one embodiment, a biodegradable synthetic matrix (e.g., a VICRYL® non-woven PG910) is placed on a resected surface followed by application of a biosynthetic adhesive (e.g., albumin and PEG-SG adhesive solution) on top of the synthetic PG910 mesh. Following one to five minutes, the synthetic matrix and biosynthetic adhesive combination preferably forms a sealant at the resected surface.

[0114] In one embodiment, a biosynthetic adhesive (e.g., in liquid form) may be applied to a synthetic matrix and the synthetic matrix is then applied to the resected tissue.

[0115] In one embodiment, a biosynthetic adhesive (e.g., in liquid form) may be applied to the resected tissue and the synthetic matrix is then applied to the resected tissue and contacts the pre-applied biosynthetic adhesive.

[0116] In one embodiment, after the synthetic matrix is placed onto the resected surface, additional biosynthetic adhesive may be applied onto the placed synthetic matrix.

[0117] In one embodiment, PEG-SG (and possibly also albumin) is pre-coated on the synthetic matrix (e.g., a VICRYL® PG910 mesh) and the synthetic matrix is applied dry on wet resected tissue to achieve sealing.

[0118] In one embodiment, the PEG-SG and albumin components of the biosynthetic adhesive are applied to the resected tissue as a powder mixture followed by placement of a dry synthetic matrix (e.g., a VICRYL® PG910 mesh) on a wet resected tissue to achieve sealing. Dry storage preferably enables longer term storage of the product at room temperature. In certain preferred embodiments, the powder mixture may have the following ratios of PEG-SG to protein (albumin): 0/100%, 20/80%, 40/60%, 50%50, 60/40%, 80/20% and 100/0% PEG-SG to albumin, respectively.

[0119] In one embodiment, the PEG-SG may be pre-coated on the synthetic substrate (e.g., the VICRYL® PG910 mesh), and the albumin solution may be applied to the synthetic matrix and/or the resected tissue, and the synthetic matrix may be applied immediately to the resected tissue to achieve sealing.

[0120] In another embodiment, the mesh can be used as a buttress material for linear staple with wide edges (wider than the linear anvil; as described in Disclosure #150334 Design of stapler anvil for delivery of buttress material wider than the anvil width) followed by application of fluid adhesive on the mesh to provide sealing of exposed tissue (during soft organ resection using linear stapler, for example)

[0121] Example 1. Use of the Synthetic Matrix and the Biosynthetic Adhesive as a Sealant in a Porcine Model of Liver Resection. The systems, devices and methods disclosed herein were used as a sealant in a porcine model of liver resection as follows. The liver lobe was resected using a surgical scalpel and the liver was clamped to minimize blood flow to the resected lobe. A biosynthetic adhesive solution was prepared as follows: a dual syringe system (e.g., Evicel device) holding 5 ml in each syringe of 1) 20% albumin solution, and 2) 150 mg/ml of PEG-SG solution. The content of the two syringes was mixed in the spray tip of the device as it was sprayed onto the resected liver surface (e.g., about 5 ml). Then, the synthetic mesh (e.g., non-woven VICRYL® PG910 mesh) was placed on the resected surface. The synthetic matrix preferably conforms to the geometry of the resected tissue. Additional biosynthetic adhesive (e.g., about 5 ml) was sprayed on the synthetic matrix with no pressure applied to the synthetic matrix. After two minutes, the clamp was removed to restore normal blood flow to the resected lobe. No bleeding or fluid leaks from the resected surface were visually observed. After the adhesive cures, sutures may be passed through the cured sealant device (i.e., a combination of the synthetic mesh and the cured adhesive) to help secure the sealant device to the resected organ. The cured sealant device may serve as a buttress to reduce stress around the suture holes. Following several minutes, the sealant was removed, which required significantly high force due to strong adhesion of the synthetic matrix and the biosynthetic adhesive to the resected tissue and re-bleeding was observed. The Example 1 study demonstrates the efficiency of the sealing systems, devices and methods disclosed herein and its superiority over other tested matrices with the same adhesives.

[0122] FIGS. 19A-19G show the implementation of Example 1 including the PG910 Mesh and Liquid albumin/PEG-SG adhesive combination being used as a sealant in a porcine model of liver resection. FIG. 19A shows a resected surface and clamped liver lobe. FIG. 19B shows the adhesive sealant being sprayed onto the resected surface. FIG. 19C shows the synthetic matrix 102 (e.g., VICRYL® PG910 mesh) being placed on the sprayed resected surface. FIG. 19D shows the synthetic matrix 102 after being sprayed with the biosynthetic adhesive sealant. FIG. 19E shows the two minutes waiting period for enabling the biosynthetic adhesive to cure. FIG. 19F shows clamp removal and re-establishment of blood flow to the resected lobe, whereby no bleeding is observed in the treated areas. Following sealant polymerization, the VICRYL® mesh combined with albumin/PEG-SG demonstrated sufficient efficacy as a sealant. FIG. 19G shows the resected surface after the sealant has been peeled away, which results in additional bleeding from the resected surface.

[0123] Example 2. Use of the sealant system during a solid tumor resection procedure. In a lung tumor resection procedure, the sealant system is used for patients undergoing a pulmonary resection. Immediately following tumor resection in the operating room, a sealing system including a synthetic matrix and a biosynthetic adhesive was placed at the areas of risk of leaks (e.g., a staple line, raw and denuded pleura surfaces) to achieve sealing at the resected area(s). The sealing system was applied to the resected organ using laparoscopic and non-laparoscopic methods. Studies demonstrated the efficacy of the synthetic matrix and biosynthetic adhesive combination in sealing pulmonary air leaks, as compared to other matrices used with fibrin glue.

[0124] In one embodiment, the sealing systems, devices and methods disclosed herein utilize a two component sealant including a synthetic matrix and a biosynthetic adhesive. The two component sealant provides surgeons with more flexibility in sealing resected tissue by enabling surgeons to apply a biosynthetic adhesive on both a synthetic matrix and/or the resected tissue prior to placing the synthetic matrix on the resected tissue. In one embodiment, after the synthetic matrix has been positioned over the resected tissue, supplemental biosynthetic adhesive may be applied at specific locations, as needed.

[0125] In one embodiment, the synthetic matrix of the two component sealing system is flexible for conforming to uneven surfaces, such as an uneven resected surface of an organ.

[0126] In one embodiment, the synthetic matrix provides enhanced structural support (i.e., scaffolding) that is substantially greater than that which can be attained by using a liquid sealant by itself.

[0127] In one embodiment, the two component sealing system is designed to seal resected surfaces for preventing and/or controlling bleeding, fluid leaks and air leaks.

[0128] The sealing system disclosed herein is independent of a patient's clotting system. Thus, surgeons can attain hemostasis and sealing independent of the patient's coagulation status, which could be impaired in patients being resected since most clotting proteins are produced in the liver. The sealing system may also be used for patients on antiplatelet and anticoagulant therapy, e.g., aspirin, heparin or warfarin.

[0129] In one embodiment, the two component sealing system is clear and allows surgeons to visually examine the resected surface following sealing. Surgeon visibility and confirmation that treatment is effective is critical and cannot be achieved with opaque liquid sealants and/or or opaque patches. In one embodiment, the sealant clarity may reduce the likelihood of iatrogenic injury due to poor visualization at the resection site.

[0130] In one embodiment, the two component dealing system disclosed herein preferably provides strong adhesion to resected tissue, however, the synthetic matrix may be manually removed and repositioned, if necessary, for forming a proper seal. In one embodiment, the combination of the synthetic matrix and the biosynthetic adhesive provide strong adhesion to resected tissue through direct covalent bonding with proteins on the tissue surface.

[0131] In one embodiment, the two component sealing system enables the properties of the respective components of the system to be modified to optimize retention of the biosynthetic adhesive by the synthetic matrix, and penetration of the biosynthetic adhesive through the thickness of the synthetic matrix. As a result, the specific formulations of the biosynthetic adhesive and the synthetic matrix may be modified to allow for specific characteristics (e.g., degradation rate, strength).

[0132] In one embodiment, the adhesive may include a synthetic adhesive. In one embodiment, the adhesive may include a biocompatible, reactive electrophile and a nucleophile. In one embodiment, the electrophile may include PEG-SG. In one embodiment, the nucleophile may be selected from any source of NH.sub.2 group, any appropriate protein or protein mixture, albumin, polyethylene glycol amines (PEG-NH.sub.2), and combinations of albumin and PEG-N H.sub.2.

[0133] While the foregoing is directed to embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, which is only limited by the scope of the claims that follow. For example, the present invention contemplates that any of the features shown in any of the embodiments described herein, or incorporated by reference herein, may be incorporated with any of the features shown in any of the other embodiments described herein, or incorporated by reference herein, and still fall within the scope of the present invention.